Reviewing Auspex Pharmaceuticals (ASPX) & The Competition
Auspex Pharmaceuticals (NASDAQ: ASPX) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Auspex Pharmaceuticals to related businesses based on the strength of its risk, institutional ownership, dividends, profitability, earnings, analyst recommendations and valuation.
Valuation and Earnings
This table compares Auspex Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Auspex Pharmaceuticals Competitors||$290.27 million||$35.99 million||56.43|
This table compares Auspex Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auspex Pharmaceuticals Competitors||-5,443.85%||-164.39%||-36.43%|
Insider & Institutional Ownership
49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of current ratings and recommmendations for Auspex Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auspex Pharmaceuticals Competitors||1134||3423||11925||240||2.67|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.66%. Given Auspex Pharmaceuticals’ rivals higher probable upside, analysts plainly believe Auspex Pharmaceuticals has less favorable growth aspects than its rivals.
Auspex Pharmaceuticals rivals beat Auspex Pharmaceuticals on 6 of the 8 factors compared.
Auspex Pharmaceuticals Company Profile
Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.
Receive News & Ratings for Auspex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auspex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.